Triazole phenotypes and genotypic characterization of clinical Aspergillus fumigatus isolates in China

References

• Kosmidis C, Denning DW.The clinical spectrum of pulmonary aspergillosis. Thorax 2015;70: 270–277.
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR 3rd, Denning DWet al.Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016;63: e1–e60.
   PubMed Web of Science ®Google Scholar
• Tashiro T, Izumikawa K, Tashiro Met al.Diagnostic significance of Aspergillus species isolated from respiratory samples in an adult pneumology ward. Med Mycol 2011;49: 581–587.
   PubMed Web of Science ®Google Scholar
• Denning DW, Cadranel J, Beigelman-Aubry Cet al.Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J 2016;47: 45–68.
   PubMed Web of Science ®Google Scholar
• Kohno S, Izumikawa K.Posaconazole for chronic pulmonary aspergillosis: the next strategy against the threat of azole-resistant Aspergillus infection. Clin Infect Dis 2010;51: 1392–1394.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Raad II, Marr KAet al.Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016;387: 760–769.
   PubMed Web of Science ®Google Scholar
• Meis JF, Chowdhary A, Rhodes JLet al.Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Philos Trans R Soc Lond B Biol Sci 2016;371 (pii): 20150460.
   PubMed Web of Science ®Google Scholar
• Howard SJ, Cerar D, Anderson MJet al.Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009;15: 1068–1076.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Chowdhary A, Melchers WJet al.Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis 2016;62: 362–368.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Ananda-Rajah M, Andes Det al.International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat 2015;21-22: 30–40.
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Watanabe A, Ito Jet al.Antifungal susceptibility of Aspergillus fumigatus clinical isolates collected from various areas in Japan. J Infect Chemother 2014;20: 336–338.
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Kathuria S, Randhawa HSet al.Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 2012;67: 362–366.
   PubMed Web of Science ®Google Scholar
• Wu CJ, Wang HC, Lee JCet al.Azole-resistant Aspergillus fumigatus isolates carrying TR(3)(4)/L98H mutations in Taiwan. Mycoses 2015;58: 544–549.
   PubMed Web of Science ®Google Scholar
• Lockhart SR, Frade JP, Etienne KAet al.Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob Agents Chemother 2011;55: 4465–4468.
   PubMed Web of Science ®Google Scholar
• Chen Y, Lu Z, Zhao Jet al.Epidemiology and molecular characterizations of azole resistance in clinical and environmental Aspergillus fumigatus isolates from China. Antimicrob Agents Chemother 2016;60: 5878–5884.
   PubMed Web of Science ®Google Scholar
• Liu M, Zeng R, Zhang Let al.Multiple cyp51A-based mechanisms identified in azole-resistant isolates of Aspergillus fumigatus from China. Antimicrob Agents Chemother 2015;59: 4321–4325.
   PubMed Web of Science ®Google Scholar
• Chen J, Li H, Li Ret al.Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother 2005;55: 31–37.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Castanheira M, Messer SAet al.In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program. 2010 through 2012. Mycoses 2015;58: 209–214.
   Google Scholar
• Ashu EE, Hagen F, Chowdhary Aet al.Global population genetic analysis of Aspergillus fumigatus. mSphere 2017;2: e00019-17.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Diekema DJ, Fothergill Aet al.Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J Clin Microbiol 2010;48: 3251–3257.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado Eet al.Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother 2008;52: 2468–2472.
   PubMed Web of Science ®Google Scholar
• Pfaller M, Boyken L, Hollis Ret al.Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J Clin Microbiol 2011;49: 586–590.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Cuenca-Estrella M, Fothergill Aet al.Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother 2011;55: 5150–5154.
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Chowdhary A, Gonzalez GMet al.Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method. Antimicrob Agents Chemother 2013;57: 3823–3828.
   PubMed Web of Science ®Google Scholar
• Arikan S, Gur D, Akova M.Comparison of Etest, microdilution and colorimetric dilution with reference broth macrodilution method for antifungal susceptibility testing of clinically significant Candida species isolated from immunocompromised patients. Mycoses 1997;40: 291–296.
   PubMed Web of Science ®Google Scholar
• Ozmerdiven GE, Ak S, Ener Bet al.First determination of azole resistance in Aspergillus fumigatus strains carrying the TR34/L98H mutations in Turkey. J Infect Chemother 2015;21: 581–586.
   PubMed Web of Science ®Google Scholar
• Hall T.BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp Ser 1999;41: 95–98.
   Google Scholar
• de Valk HA, Meis JF, Curfs IMet al.Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates. J Clin Microbiol 2005;43: 4112–4120.
   PubMed Web of Science ®Google Scholar
• Kidd SE, Goeman E, Meis JFet al.Multi-triazole-resistant Aspergillus fumigatus infections in Australia. Mycoses 2015;58: 350–355.
   PubMed Web of Science ®Google Scholar
• Tashiro M, Izumikawa K, Minematsu Aet al.Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob Agents Chemother 2012;56: 584–587.
   PubMed Web of Science ®Google Scholar
• Steinmann J, Hamprecht A, Vehreschild MJet al.Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother 2015;70: 1522–1526.
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Sharma C, Kathuria Set al.Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia. Front Microbiol 2015;6: 428.
   PubMed Web of Science ®Google Scholar
• Gregson L, Goodwin J, Johnson Aet al.In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole. Antimicrob Agents Chemother 2013;57: 5778–5780.
   PubMed Web of Science ®Google Scholar
• Guinea J, Pelaez T, Recio Set al.In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008;52: 1396–1400.
   PubMed Web of Science ®Google Scholar
• Howard SJ, Lass-Florl C, Cuenca-Estrella Met al.Determination of isavuconazole susceptibility of Aspergillus and Candida species by the EUCAST method. Antimicrob Agents Chemother 2013;57: 5426–5431.
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Messer SA, Hollis RJet al.Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003;41: 3623–3626.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJet al.Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002;46: 1032–1037.
   PubMed Web of Science ®Google Scholar
• Verweij PE, Snelders E, Kema GHet al.Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 2009;9: 789–795.
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Sharma C, Meis JF.Azole-resistant aspergillosis: epidemiology, molecular mechanisms, and treatment. J Infect Dis 2017;216: S436–S444.
   PubMed Web of Science ®Google Scholar
• Camps SM, Dutilh BE, Arendrup MCet al.Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS One 2012;7: e50034.
   PubMed Web of Science ®Google Scholar
• Hagiwara D, Takahashi H, Watanabe Aet al.Whole-genome comparison of Aspergillus fumigatus strains serially isolated from patients with aspergillosis. J Clin Microbiol 2014;52: 4202–4209.
   PubMed Web of Science ®Google Scholar
• Abdolrasouli A, Rhodes J, Beale MAet al.Genomic context of azole resistance mutations in Aspergillus fumigatus determined using whole-genome sequencing. MBio 2015;6: e00536.
   PubMed Web of Science ®Google Scholar
• Leonardelli F, Theill L, Nardin MEet al.First itraconazole resistant Aspergillus fumigatus clinical isolate harbouring a G54E substitution in Cyp51Ap in South America. Rev Iberoam Micol 2017;34: 46–48.
   PubMed Web of Science ®Google Scholar
• Sharma C, Hagen F, Moroti Ret al.Triazole-resistant Aspergillus fumigatus harbouring G54 mutation: is it de novo or environmentally acquired? J Glob Antimicrob Resist 2015;3: 69–74.
   PubMed Web of Science ®Google Scholar
• Mosquera J, Sharp A, Moore CBet al.In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother 2002;50: 189–194.
   PubMed Web of Science ®Google Scholar